Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer.

Pamukuntla M, Ohemeng A, Banjara B, Kotina M, Pope JL, Ali S, Darling-Reed S, Burow ME, Gangapuram M, Eyunni S, Thomas J, Hilliard A, Davidson AM, Henderson E, Tilghman SL

Open source

DOI: 10.3389/fphar.2026.1852788
Published: 2026
Container: Frontiers in pharmacology
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3389/fphar.2026.1852788,
  title = {Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer.},
  author = {Pamukuntla M and Ohemeng A and Banjara B and Kotina M and Pope JL and Ali S and Darling-Reed S and Burow ME and Gangapuram M and Eyunni S and Thomas J and Hilliard A and Davidson AM and Henderson E and Tilghman SL},
  year = {2026},
  journal = {Frontiers in pharmacology},
  doi = {10.3389/fphar.2026.1852788},
  url = {https://doi.org/10.3389/fphar.2026.1852788}
}

RIS

TY  - JOUR
TI  - Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer.
AU  - Pamukuntla M
AU  - Ohemeng A
AU  - Banjara B
AU  - Kotina M
AU  - Pope JL
AU  - Ali S
AU  - Darling-Reed S
AU  - Burow ME
AU  - Gangapuram M
AU  - Eyunni S
AU  - Thomas J
AU  - Hilliard A
AU  - Davidson AM
AU  - Henderson E
AU  - Tilghman SL
PY  - 2026
JO  - Frontiers in pharmacology
DO  - 10.3389/fphar.2026.1852788
UR  - https://doi.org/10.3389/fphar.2026.1852788
ER  -

APA

M, P., A, O., B, B., M, K., JL, P., S, A., S, D., ME, B., M, G., S, E., J, T., A, H., AM, D., E, H., & SL, T. (2026). Pharmacologic targeting of midasin (MDN1) reveals a potential therapeutic vulnerability in ESR1-mutant breast cancer.. Frontiers in pharmacology. https://doi.org/10.3389/fphar.2026.1852788

Source records

pubmed · retrieved 2026-09-26T00:30:47.381Z